Overview
- The medicine can be prescribed privately in the UK until NICE rules on routine NHS funding.
- The oral JAK inhibitor is recommended at 8 mg twice daily for adults with severe disease.
- Approval is supported by two studies in 1,223 adults who had at least 50% scalp hair loss for more than six months.
- After 24 weeks, about 30% achieved at least 80% scalp hair coverage and about 23% achieved at least 90%.
- Headache and acne were the most common adverse events, and the MHRA will continue post-marketing safety surveillance.